GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Operating Margin %

BioLine Rx (BioLine Rx) Operating Margin % : -247.17% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. BioLine Rx's Operating Income for the three months ended in Dec. 2023 was $-11.86 Mil. BioLine Rx's Revenue for the three months ended in Dec. 2023 was $4.80 Mil. Therefore, BioLine Rx's Operating Margin % for the quarter that ended in Dec. 2023 was -247.17%.

The historical rank and industry rank for BioLine Rx's Operating Margin % or its related term are showing as below:

BLRX' s Operating Margin % Range Over the Past 10 Years
Min: -895.66   Med: -895.66   Max: -895.66
Current: -895.66


BLRX's Operating Margin % is ranked worse than
71.54% of 1026 companies
in the Biotechnology industry
Industry Median: -175.525 vs BLRX: -895.66

BioLine Rx's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

BioLine Rx's Operating Income for the three months ended in Dec. 2023 was $-11.86 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-42.99 Mil.


BioLine Rx Operating Margin % Historical Data

The historical data trend for BioLine Rx's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Operating Margin % Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -895.67

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -247.17

Competitive Comparison of BioLine Rx's Operating Margin %

For the Biotechnology subindustry, BioLine Rx's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Operating Margin % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Operating Margin % falls into.



BioLine Rx Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

BioLine Rx's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-42.992 / 4.8
=-895.67 %

BioLine Rx's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-11.864 / 4.8
=-247.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLine Rx  (NAS:BLRX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


BioLine Rx Operating Margin % Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (BioLine Rx) Headlines

From GuruFocus